TABLE 3
LP, EP, and EF in 2 Studies of Phase 3 (CCK-1 and CCK-2 doses) for 44 Patients Each
Dose
Mean (SD)
LP (min)
EP (min)
EF (%)
CCK-1
5.2 (3.7)
27.8 (8.9)
25.2 (8.2)
CCK-2
5.0 (3.5)
28.9 (8.1)
31.1 (17.7)